AC Immune Announces Successful Closing of Second Subscription Rights Offering
July 31 2018 - 4:06PM
Gross Proceeds of All Three Offerings of 10
Million Common Shares in Total Aggregate to USD 117.5
Million
Lausanne, Switzerland, July 31, 2018 - AC
Immune, SA (NASDAQ: ACIU), a Swiss-based, clinical-stage
biopharmaceutical company focused on neurodegenerative diseases,
today announced the closing of its previously announced second
subscription rights offering to eligible shareholders to subscribe
for 1,500,000 newly issued common shares at a price per common
share of USD 11.75, for gross proceeds of USD 17.6 million. As
previously announced, on July 23, 2018, AC Immune closed its first
subscription rights offering and registered public offering of
8,500,000 of its common shares at an offering price of USD 11.75
per share for aggregate gross proceeds of USD 99.9 million,
bringing aggregate gross proceeds for all three offerings to USD
117.5 million.
The second subscription rights offering was made
pursuant to an effective shelf registration statement of the
Company previously filed with the U.S. Securities and Exchange
Commission. This offering was made only by means of a prospectus
supplement and the accompanying prospectus. Copies of the
prospectus for this offering may be obtained from the Company in
writing at AC Immune SA, EPFL Innovation Park Building B, 1015
Lausanne, Switzerland or via telephone by calling +41 21 345 91
21.
DisclaimerThis press release shall not
constitute an offer to sell or the solicitation of an offer to buy
any securities, nor shall there be any sale of any securities, in
any state or jurisdiction in which such an offer, solicitation or
sale would be unlawful prior to registration or qualification under
the securities laws of any such state or jurisdiction. This press
release is not a prospectus within the meaning of article 652a of
the Swiss Code of Obligations, nor is it a listing prospectus of
any exchange or regulated trading facility in Switzerland. Copies
of this press release may not be sent to jurisdictions, or
distributed in or sent from jurisdictions, in which this is barred
or prohibited by law.
About AC ImmuneAC Immune is a
clinical-stage Swiss-based biopharmaceutical company, listed on
Nasdaq, which aims to become a global leader in precision medicine
for neurodegenerative diseases. The Company designs, discovers and
develops therapeutic as well as diagnostic products intended to
prevent and modify diseases caused by misfolding proteins.
For further information, please
contact:
|
In EuropeBeatrix BenzAC Immune Corporate Communications
Phone: +41 21 345 91 34E-mail: beatrix.benz@acimmune.com |
In the USLisa SherAC Immune Investor Relations Phone: +1 970
987 26 54E-mail: lisa.sher@acimmune.com |
|
Nick Miles/Toomas KullCabinet Privé de Conseils s.a.Phone: +41 22
552 46 46 E-mail: miles@cpc-pr.com kull@cpc-pr.com |
Ted AgneThe Communications Strategy Group Inc.Phone: +1 781 631
3117E-mail: edagne@comstratgroup.com |
AC Immune (NASDAQ:ACIU)
Historical Stock Chart
From Mar 2024 to Apr 2024
AC Immune (NASDAQ:ACIU)
Historical Stock Chart
From Apr 2023 to Apr 2024
